Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.
Tirzepatide just chalked up another win in metabolic dysfunction-associated steatotic liver disease (MASLD) research. A new study out of Hebei, China, put the dual GIP/GLP-1 receptor agonist head-to-head with semaglutide and standard controls in a high-fat, high-fructose mouse model. The focus: what’s actually happening at the molecular level in the liver when these peptides are in play.
BMC Gastroenterol
by Pan Y, Song F, Liu X et al.
“Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis. Pan Y(1)(2), Song F(3)(2), Liu X(1), Zhang Y(2), Zhang J(2), Song G(2), Ren L(4). Author information: (1)School of Clinical Medicine, Hebei North University, Zhangjiakou, Hebei Province, China. (2)Department of Endocrinology, Hebei General Hospital, Peace West Road, Shijiazhuang, Hebei Province, 050000, China. (3)School of Clinical Medicine, North China University of Science and Technolog, Tangshan, Hebei Province, China. (4)Department of Endocrinology, Hebei General Hospital, Peace West Road, Shijiazhuang, Hebei Province, 050000, China. renluping1122@163.com. BACKGROUND/OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common multisystem chronic progressive liver disease with a rising burden. Tirzepatide (TZP), a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown beneficial hepatic effects, but the related molecular mechanisms remain unclear. The aim of this study was to investigate the hepatic molecular signatures associated with TZP in MASLD. METHODS: A MASLD mouse model was established using a high-fat, high-fructose (HFHFr) diet. Male C57BL/8J mice (n = 32) were randomized to four groups: control (CON), HFHFr, HFHFr + semaglutide (Sema), and HFHFr + TZP. Hepatic transcriptomic and proteomic profiles were generated by RNA sequencing and liquid chromatography-mass spectrometry (LC-MS), respectively. Key molecular targets were validated by quantitative real-time PCR and immunoblotting of liver tissue. RESULTS: HFHFr feeding induced hyperglycaemia, increased HOMA-IR, elevated ALT/AST, and marked hepatic steatosis and inflammatory injury. Both Sema and TZP ameliorated these abnormalities. TZP was associated with lower hepatosomatic index, improved fasting glucose and HOMA-IR, and reduced hepatic MCP-1, IL-1β, TNF-α and GSDMD, with partial restoration of IL-10. Integrated liver transcriptomic-proteomic profiling highlighted chemokine signaling and PI3K-AKT pathway signatures to be associated with TZP. Further targeted validation showed that TZP treatment was associated with reduced hepatic CCL2/CCR2 axis components, and decreased PI3K abundance and lower AKT phosphorylation. CONCLUSION: TZP ameliorated hepatic steatosis and attenuated inflammatory responses in HFHFr-induced MASLD and was associated with downregulation of the CCL2/CCR2-linked chemokine signaling and PI3K-AKT-related inflammatory responses. © 2026. The Author(s). Conflict of interest statement: Declarations. Ethics approval and consent to participate: The animal study protocol was approved by the Ethics Committee of Hebei General Hospital (protocol code 2025DW002) on January 9, 2025. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.”
Here’s the breakdown:
Mice on the junk-food diet predictably developed all the MASLD hallmarks: high blood sugar, insulin resistance, fatty, inflamed livers.
Both semaglutide and tirzepatide improved these metrics, but tirzepatide pulled ahead in a few key areas—lower liver mass, better fasting glucose, and improved insulin sensitivity.
Tirzepatide also dialed down several inflammatory signals in the liver, including MCP-1, IL-1β, TNF-α, and GSDMD, while nudging anti-inflammatory IL-10 back up.
The researchers dug deeper with transcriptomic and proteomic profiling. Chemokine signaling and the PI3K-AKT pathway rose to the top as key molecular signatures linked to tirzepatide’s effect.
Targeted validation confirmed: tirzepatide reduced hepatic expression of the CCL2/CCR2 axis and tamped down PI3K and AKT activation.
Key takeaway: in this MASLD model, tirzepatide isn’t just making numbers look better—it’s actively shifting the inflammatory and metabolic pathways that drive liver damage. That’s a solid signal for anyone researching peptide mechanisms in metabolic disease.
If you’re comparing peptide options or looking for sourcing, check the vendor directory for up-to-date listings. The research community keeps pushing the envelope, and studies like this make it clear: peptide science is bringing real answers.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.